Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

INTRODUCTION: A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection. We conducted a phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Rui, Kong, Fei, Li, Guangming, Wen, Xiaofeng, Zhang, Yuexin, Yang, Xingxiang, Meng, Chenxin, Xie, Wen, Jiang, Yongfang, Wang, Xiaozhong, Han, Xueji, Huang, Yan, Mao, Qing, Wang, Jiefei, Guan, Yujuan, Chen, Jiayu, Ma, Yingjie, Xiong, Qingfang, Ma, Hong, Yan, Xuebing, Rao, Huiying, Zhao, Yingren, Sun, Tong, Zhu, Liying, Mao, Xiaorong, Lian, Jianqi, Deng, Guojiong, Xin, Yongning, Wang, Yifei, Ye, Yinong, Xu, Bin, Gao, Hainv, Tan, Youwen, Li, Dongliang, Yang, Dongliang, Su, Minghua, Zhang, Xiaomeng, Min, Jie, Shi, Xinsheng, Wei, Lai, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651614/
https://www.ncbi.nlm.nih.gov/pubmed/37856013
http://dx.doi.org/10.1007/s40121-023-00872-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651614/
https://www.ncbi.nlm.nih.gov/pubmed/37856013
http://dx.doi.org/10.1007/s40121-023-00872-4

Ejemplares similares